CCCCNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31

C4 Therapeutics, Inc.

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 11, 2026

$2.89+0.13 (+4.52%)

Close on Oct 19, 2026

Market cap: $377.71M
P/E (TTM): –
Dividend yield: –

C4 Therapeutics, Inc. income statement

Annual Quarterly TTM

Millions of USD, except per-share data. Shares in millions.

Line item	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31	FY 2020 2020-12-31	FY 2019 2019-12-31
Revenue	36	36	21	31	46	–	–
Research & Development	104	111	118	118	95	78	48
General & Administrative	36	42	42	43	33	15	8.77
Operating Expenses	151	155	160	161	128	94	57
Operating Income	-115	-120	-139	-130	-82	-60	-35
Other Non-Operating Income	10	14	7.82	1.36	-1.76	-6.51	2.16
Merger & Restructuring Charges	0	2.44	0	–	–	–	–
Gain (Loss) on Sale of Assets	–	–	–	–	–	–	-0.02
Pretax Income	-105	-105	-131	-128	-84	-67	-33
Income Tax Expense	0.12	0.13	1.28	0	0	-0.63	0.80
Net Income incl. Noncontrolling Interests	–	–	–	–	-84	-66	-34
Net Income	-105	-105	-132	-128	-84	-66	-34
Preferred Dividends	–	–	–	–	–	–	8.47
Net Income to Common	–	–	–	–	-84	-66	-43
EPS (Basic)(per share)	-1.27	-1.52	-2.67	-2.62	-1.82	-5.83	-31.03
EPS (Diluted)(per share)	-1.27	-1.52	-2.67	-2.62	-1.82	-5.83	-31.03
Shares Outstanding (Basic, Weighted)(shares)	83	69	50	49	46	11	1.37
Shares Outstanding (Diluted, Weighted)(shares)	83	69	50	49	46	11	1.37
EBITDA	-113	-118	-137	-128	-81	-59	-34

Italic numbers are calculated by StockData (for example Q4 = full year − nine months). Per-share data and share counts are adjusted for stock splits. Hover a number for its source; click it to open the filing on SEC.gov. Click a row to chart it.

Ratios

Latest available, balances at Jun 30, 2026

Profitability, TTM

Gross margin: –
Operating margin: -319.0%
Net margin: -289.4%
Return on equity, FY2025: -44.4%

Financial strength

Current ratio: 5.45
Debt to equity: –
Debt to assets: –
Cash to current liabilities: 162.9%

Valuation

P/E ratio: –
Price to sales: 10.78
Price to book: 1.53
Dividend yield: –